Asthma Clinical Trial
Official title:
Prospective Open Pilot of Low vs. Higher Dose Vitamin D in D-deficient Asthmatic Children: Does Diet Predict Immune Function and Asthma Symptom Response to Vitamin D Supplementation?
This is a pilot randomized controlled trial of lower vs. higher dose vitamin D
supplementation in D-deficient asthmatic children, to determine necessary sample sizes for
outcome measures in a larger multisite study, and to examine possible relationships and
effect sizes between various biological markers that may be important to the pathophysiology
of childhood asthma.
Aims of the study are to:
1. Evaluate effect sizes for relationships between serum 25OH-vitD and omega-fatty acid
(FA) biomarkers, before and after supplementation with lower or higher dose vitamin D,
on immune function, and asthma severity.
2. Characterize changes in innate and adaptive immune function and inflammatory responses
in asthmatic D-deficient youth at baseline and after vitD supplements, by dietary
O6:O3FA status and vitD dose.
An estimated up to 120 youth meeting eligibility criteria will be screened for vitamin D
deficiency, and if found deficient, will be offered enrollment in this study.
Eligible children who assent and whose parent/guardian consent to participate will be
randomized to low dose vs. higher dose vitamin D to take across a 3-month period of time.
Blood, questionnaires, and pulmonary function tests will be obtained at baseline and end of
study. Weekly phone calls will check on any questions or concerns the participant or their
family may have.
Aims and Hypotheses:
Aim I: Evaluate effect sizes for relationships between omega-FA and vitD biomarkers, pre-
and post- low and higher dose vitamin D supplementation, in diet, immune function, and
asthma severity.
Aim II: Characterize changes in innate and adaptive immune function and inflammatory
responses in asthmatic D-deficient youth at baseline and after vitD supplements, by O6:O3FA
status and vitD dose.
Exploratory: Compute effect sizes/odds ratios for differences in pulmonary function,
self-reported asthma severity, depressive symptoms, hospitalization/ED visits, and
medication changes based on treatment group.
Effect sizes will be calculated for all continuous outcome variables by:
Effect Size (ES) = Average of the post-test scores - Average of the pre-test scores Average
standard deviation
Odds ratios for the categorical asthma severity variable will be computed through logistic
regression by treatment group with no covariates.
Examine differences in pulmonary function tests, self-reported asthma severity, depressive
symptoms, hospitalization/ED visits, and medication changes based on treatment group. Omega
fatty acid intake and allergic status will be included as potentially mediating variables.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|